This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
WALL analysts changed outlook on top names. See upgrades, downgrades & initiations on analyst ratings page. Workday downgraded, price target cut.
Stocks · News reference
Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'
Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported better-than-expected earnings. Rockwell Automation and Neurocrine Biosciences had mixed reactions from analysts. Uber and Amcor shares fell, while Tanger, Rockwell Automation, and Neurocrine Biosciences shares all had varying degrees of movement.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Downgrades Amcor to Neutral, Raises Price Target to $47
JP Morgan analyst Jeffrey Zekauskas downgrades Amcor (NYSE:AMCR) from Overweight to Neutral and raises the price target from $44 to $47.
Citigroup Maintains Buy on Amcor, Raises Price Target to $52
Citigroup analyst Anthony Pettinari maintains Amcor (NYSE:AMCR) with a Buy and raises the price target from $47 to $52.
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Neurocrine Biosciences has received FDA IND acceptance for a Phase 2 study of NBI-1117567, an oral muscarinic M1/M4 selective agonist for Alzheimer's cognition. Nxera Pharma will receive a $10 million milestone payment. This marks the third compound in Nxera's muscarinic agonist portfolio to advance to Phase 2, following direclidine in Phase 3 and NBI-1117570 in Phase 2.
Neurocrine Receives FDA Investigational New Drug Acceptance For NBI-1117567 Phase 2 Alzheimer's Study, Triggering $10M Payment To Nxera
NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with NeurocrineNxera to